Jove
Visualize
Contact Us

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

768
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
768
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

1.3K
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.3K
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

843
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
843
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

508
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
508
Renal Corpuscle01:20

Renal Corpuscle

8.0K
The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
8.0K
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

526
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
526

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Reply: Antithrombotic Strategies in Chronic Kidney Disease: The Importance of Exposure Definition and Temporal Alignment.

Mayo Clinic proceedings·2026
Same author

Cuffless hemodynamic monitoring with physics-informed machine learning models.

Nature communications·2026
Same author

NT-proBNP-Based Heart Failure Risk Score for Asymptomatic Diabetic Population in Asia: The DM-HEART Study.

JACC. Asia·2026
Same author

2026 Taiwan society of lipids and atherosclerosis consensus statement for the identification and management of patients receiving suboptimally tolerable statins.

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
Same author

Antithrombotic Strategies in Advanced Chronic Kidney Disease: Real-World Comparison of Oral Anticoagulation Alone vs Dual Antithrombotic Therapy.

Mayo Clinic proceedings·2026
Same author

2026 Consensus and review of Lipoprotein(a) from Taiwan Society of Lipid and Atherosclerosis: Molecular pathogenesis, epidemiology, clinical implications, and advances in diagnostic strategies.

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 26, 2026

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
12:21

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues

Published on: November 30, 2013

15.4K

MicroRNA-92a Mediates Endothelial Dysfunction in CKD.

Fenqing Shang1,2,3, Shen-Chih Wang4,5,6, Chien-Yi Hsu7,8,9

  • 1Cardiovascular Research Center, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.

Journal of the American Society of Nephrology : JASN
|July 12, 2017
PubMed
Summary

Uremic toxins in chronic kidney disease (CKD) increase microRNA-92a (miR-92a) in endothelial cells, contributing to cardiovascular disease risk. Antioxidants may mitigate these harmful effects.

Keywords:
chronic kidney diseaseendothelial cellsmicroRNA-92oxidative stress

More Related Videos

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

2.0K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.9K

Related Experiment Videos

Last Updated: Feb 26, 2026

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
12:21

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues

Published on: November 30, 2013

15.4K
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

2.0K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.9K

Area of Science:

  • Cardiovascular Biology
  • Nephrology
  • Molecular Biology

Background:

  • Chronic kidney disease (CKD) is a significant risk factor for cardiovascular disease (CVD).
  • Uremic toxins accumulating in CKD promote oxidative stress and endothelial dysfunction, key contributors to CVD.
  • MicroRNA-92a (miR-92a), induced by oxidative stress in endothelial cells (ECs), plays a role in angiogenesis and atherosclerosis.

Purpose of the Study:

  • To investigate the role of oxidative stress-responsive miR-92a in the context of CKD.
  • To determine if uremic toxins influence miR-92a levels and endothelial function.
  • To explore the potential therapeutic effect of antioxidants on these processes.

Main Methods:

  • Analysis of serum miR-92a levels in CKD patients across three clinical sites.
  • In vitro studies using cultured ECs exposed to human CKD serum or uremic toxins (indoxyl sulfate).
  • In vivo studies in adenine-induced CKD rat models, analyzing miR-92a in various tissues and microparticles.
  • Correlation analysis between serum miR-92a and indoxyl sulfate in hemodialysis patients.

Main Results:

  • Serum miR-92a levels were elevated in CKD patients, correlating with reduced kidney function.
  • CKD serum and uremic toxins increased miR-92a levels and suppressed its targets in ECs, impairing endothelial function.
  • The antioxidant N-acetylcysteine reversed these detrimental effects in vitro.
  • Increased miR-92a was observed in aortas, serum, and endothelial microparticles of CKD rats.
  • Endothelial microparticles from uremic serum carried higher levels of miR-92a compared to controls.
  • A positive correlation was found between serum miR-92a and indoxyl sulfate in ESRD patients.

Conclusions:

  • Uremic toxins in CKD upregulate miR-92a in endothelial cells.
  • Elevated miR-92a contributes to endothelial dysfunction and increases CVD risk in CKD patients.
  • Targeting miR-92a or using antioxidants presents a potential therapeutic strategy for CKD-associated cardiovascular complications.